Advertisement
The Company also announced today the re-appointment of Steve Gorlin to theBoard of Directors and the appointment of Steve Gorlin and Thomas W. D'Alonzoas Co-Chairmen of the Board of Directors. Mr. Gorlin was a founder of DARAand previously served as a director. Mr. Gorlin currently serves as Chairmanof the Board for NTC China and MiMedx, Inc. (OTC BB: AYXC.OB) and is a memberof the board of Surgi-Vision, Inc. From 1998 to 2003, Mr. Gorlin served onthe Business Advisory Council to The Johns Hopkins School of Medicine andcurrently sits on the board of The Johns Hopkins Alliance for Science andTechnology Development. Mr. D'Alonzo has served as a member of DARA's Boardsince 2005, and has served as Chief Executive Officer and a member of theBoard of Directors of MiMedx, Inc. He is also currently a Director of SalixPharmaceuticals, Inc. (NASDAQ: SLXP), BioDelivery Sciences, Inc. (NADSAQ:BDSI), Amarillo BioSciences, Inc. (OTCBB: AMAR.OB), and Plexigen, Inc. Mr.Gorlin was re-appointed to the Board to fill a vacancy created by Mr. Franco'sresignation.
Advertisement
Thomas D'Alonzo commented, "It is a pleasure to announce John'sappointment as President of DARA. John has a deep understanding of thescience behind the drugs in DARA's pipeline in addition to experience runninga company. We believe the combination of his talents as a scientist and aleader make him ideally suited to assume the role of DARA's President. At thesame time, we are deeply indebted to Richard Franco for his service to theCompany, particularly his leadership and skill in consummating the recentmerger with Point Therapeutics. We wish Richard well in his futureendeavours."
Mr. D'Alonzo also stated, "We are also pleased that Steve Gorlin hasagreed to re-join our Board. Steve has recently been involved in time-consuming projects for other companies, but has graciously agreed to return tothe DARA Board during this exciting period as we transition to Dr. Didsbury'sleadership."
Dr. Didsbury commented, "It is a privilege to assume the role of DARA'sPresident. I'm excited about DARA's product pipeline and look forward toleading the Company as it advances the development of drugs with the potentialto meaningfully improve the lives of patients suffering from ailments likeneuropathic pain, type 2 diabetes, and psoriasis. Steve Gorlin brings awealth of industry knowledge and relationships with his return to the Board,and we are fortunate to have Steve and Tom's leadership as Co-Chairmen to helpguide DARA's strategy and direction going forward."
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-baseddevelopment-stage pharmaceutical company that acquires promising therapeuticmolecules and medical technologies directly or through investment inestablished companies. DARA focuses its therapeutic development efforts onsmall molecules from late preclinical development through phase 2 clinicaltrials. DARA is developing a portfolio of therapeutic candidates forneuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemiaand dermatological disorders. DARA has licensed promising drug developmentcandidates from Kirin Pharmaceuticals of Japan, Bayer PharmaceuticalsCorporation, Massachusetts General Hospital and Nuada LLC.
For more information please contact the Company at 919-872-5578 or visitour web site at www.darabio.com.
All statements in this news release that are not h
